OBI Pharma Profit Margin

The latest profit margin for 4174.TWO is -2922.86% as of June 2026. That compares with -3906.76% in the prior-year period — up 25.2% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside OBI Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4174.TWO's profit margin moved from -3906.76% to -2922.86% — a 25.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in OBI Pharma's valuation or profitability profile.

Against Healthcare companies, 4174.TWO currently prints -2922.86% for profit margin, while the sector average sits near 21.34%. That is roughly 13799.7% below the sector mean. Large gaps often invite a closer look at OBI Pharma's growth, margins, and balance sheet.

Profit Margin shows how effectively OBI Pharma converts resources into returns. At -2922.86%, 4174.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3906.76% in the prior-year period — up 25.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 4174.TWO's profit margin (-2922.86%), review year-over-year change from -3906.76%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.